Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032766 | 0.82 | ALDH1A1 (0.58) | CD44CYP3A4ALDH1A1TP53TSHR | |
| SCHEMBL1951099 | 0.82 | CYP3A4 (0.58) | CD44CYP3A4ALDH1A1TP53TSHR | |
| Bromide SCHEMBL10949048 | 0.79 | ALDH1A1 (0.55) | CD44CYP3A4ALDH1A1TP53TSHR | |
| SCHEMBL1392591 | 0.75 | CYP3A4 (0.65) | CD44CYP3A4ALDH1A1TP53TSHR | |
| SCHEMBL899027 | 0.75 | CA1 (0.52) | CYP3A4ALDH1A1TDP1CA1CA2 | |
| SCHEMBL1830038 | 0.75 | RAPGEF4 (0.34) | CD44CYP3A4P2RX7MAPTPTGS1 | |
| SCHEMBL11140035 | 0.75 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TP53TSHRTDP1 | |
| SCHEMBL698002 | 0.75 | KDM4E (0.45) | CD44CYP3A4ALDH1A1TP53TSHR | |
| SCHEMBL5973280 | 0.75 | ALDH1A1 (0.43) | CD44CYP3A4ALDH1A1TP53TSHR | |
| SCHEMBL4704877 | 0.75 | ALDH1A1 (0.43) | CD44CYP3A4ALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113727713-B | Use of fluorine substituted 2-aminothiazole-5-aromatic formamide | 湖南华纳大药厂股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-3532474-B1 | 4,5-ANNULATED 1,2,4-TRIAZOLONES | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-114921391-B | 4, 5-cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-17 | — | — | US | disclosed |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023028056-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ACEMOGLU MURAT | 2008-10-09 | — | — | US | disclosed |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ACEMOGLU MURAT | 2008-10-09 | — | — | US | disclosed |
| CN-100412053-C | Process for preparation of phenylacetic acid derivatives | NOVARTIS AG (CH) | 2008-08-20 | — | — | CN | disclosed |
| CN-1377337-A | Process for preparation of phenylacetic acid derivatives | NOVARTIS AG (CH) | 2002-10-30 | — | — | CN | disclosed |
| EP-1216226-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | Novartis AG (CH) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023346-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-04-05 | — | — | WO | disclosed |
| US-4326075-A | ANTIDIARRHEA AGENTS | WILLIAM H. RORER, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4203920-A | ANTIDIARRHEAL | WILLIAM H. RORER, INC. (US) | 1980-05-20 | — | — | US | disclosed |
| US-4147804-A | ANTIARRHYTHMIA AGENTS | WILLIAM H. RORER, INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4060635-A | Amidinoureas for treating diarrhea | WILLIAM H. RORER, INC. (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | CD44 4130/4885CYP3A4 4002/4885ALDH1A1 1207/4885 |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | CD44 2465/4885CYP3A4 1895/4885ALDH1A1 332/4885 |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ALDH7A1, CYP4F11, CYP2A6 | CD44 2542/4885CYP3A4 32/4885ALDH1A1 111/4885 |
| US-11787797-B2 | 4,5-annulated 1,2,4-triazolones | CCNA1, CCNT1, CCND2 | CD44 4673/4885CYP3A4 99/4885ALDH1A1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.